Study Evaluating The Efficacy And Safety Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced-Constipation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary purpose of this study is to evaluate the safety, efficacy, and tolerability of subcutaneous (injection beneath the skin) MOA-728 versus placebo in Asian Adult subjects with opioid-induced constipation and advanced illness
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men and women who are at least 18 years of age, and who have a diagnosis of advanced illness with anticipated life expectancy >= 1 month;
Is receiving a regular dose of opioids for the control of pain;
Has a diagnosis of opioid induced constipation;
Is on a stable laxative regimen.
Has a known or suspected mechanical gastrointestinal obstruction, or any potential non-opioid cause of bowel dysfunction contributed to constipation;
Has evidence of current fecal impaction;
Has evidence of active diverticulitis, or peritonitis, or a history of bowel surgery within 30 days before test article administration;
Has a boy weight less t han 27 kg
Has any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.